Bioventix Plc · LSE:BVXP
Bioventix — Investor Presentation (October 2022)
15 slides from Bioventix's investor presentation, Oct 24, 2022
Slide 1: Bioventix plc
1 Bioventix plc 24 October 2022
Slide 2: Antibodies and Blood Testing
2 Antibodies and Blood Testing ▪Bioventix creates and manufactures sheep monoclonal antibodies (SMAs). Customers incorporate these antibodies in reagent packs for use on automated blood-testing machines antigen antibody ▪Superior antibodies can facilitate improved tests ▪Bioventix sells liquid “phys
Slide 3: Diagnostic Applications for SMAs
3 Diagnostic Applications for SMAs Vitamin D Thyroid function Fertility Chest pain; heart attack Drug testing (25-OH vitamin D) (thyroxine, T3) (testo, estrogens) (troponin) (THC) ▪Bioventix has a portfolio of ~20 antibodies that are sold globally to in vitro diagnostics (IVD) companies ▪Most have b
Slide 4: Antibodies and Business Dynamics
4 Antibodies and Business Dynamics ▪Projects can be internally driven or sponsored by customers +1 year Prototype test Old test 2-4 years ▪Bioventix takes about 1 year to create new antibodies = 3-5 years total ▪Even for established diagnostics, customers take 2-4 years to prototype tests, conduct f
Slide 5: Key Year End Financials
5 Key Year End Financials £ (‘000) year to Finncap year to 30.6.21 forecast 30.6.22 2021/22 Sales 10,930 10,400 11,720 (+7%) P/(L) before tax 8,120 8,000 9,280 (adjusted) (+14%) P/(L) after tax 6,730 6,700 7,670 (adjusted) (+14%) Period-end cash 6,500 5,200 6,130 Total regular dividend per share (p)
Slide 6: NT-proBNP revenues replaced by troponin and other antibodies
6 ▪The expiry of NT-proBNP revenues has been replaced by growth in troponin and other antibodies
Slide 7: Additional Sales Commentary
7 Additional Sales Commentary ▪ Many core revenue streams have recovered during 2022 • The impact of the coronavirus pandemic on routine blood testing in many geographical areas receded during 1H.2022 • vitamin D sales have also benefitted from this effect ▪ Troponin sales have increased significant
Slide 8: Longer Term Pipeline Development
8 Longer Term Pipeline Development high Amyloid (Pre-Diagnostics) Tau (Alzheimers, own-risk) ← Increasing potential value Secretoneurin (CardiNor) medium Biotin blockers [1] Low Industrial biomonitoring THC (sandwich) [1] (benzene, isocyanates) Pyrene biomonitoring Low Medium high Increasing probabi
Slide 9: Pipeline Development Commentary
9 Pipeline Development Commentary ▪ Secretoneurin (CardiNor/cardiac): data from recent patient sample studies does show a link with heart disease read-outs. The next step for CardiNor will be to define the potential utility of secretoneurin diagnostics in cardiac health ▪ Amyloid (Pre-Diagnostics/Al
Slide 10: Bioventix Strategy
10 Bioventix Strategy ▪ Seek novel clinical diagnostic biomarkers that suit our antibody technology and identify partner collaborator labs ▪ Continue to focus on antibody technology development • Identify antibody creation and production technologies that are compatible with existing core SMA techno
Slide 11: Bioventix Lab, Farnham
11 Bioventix Lab, Farnham ▪ Technology development ▪ Purification and assay ▪ Cell culture ▪ Bioreactor production ▪Supply chain issues continue but have been adequately managed ▪Action has been taken to mitigate against possible power interruptions during the winter of 2022/23
Slide 12: Bioventix Directors
12 Bioventix Directors ▪Peter Harrison, CEO ▪Ian Nicholson, Chairman ▪>30 years experience of ▪>30 years experience of antibody technology at commercial development within Celltech, KS Biomedix & biotechnology including Bioventix Amersham, Celltech, Chroma, Clinigen, Consort Medical & F2G ▪Peter rem
Slide 13: Environmental, Social and Governance
13 Environmental, Social and Governance ▪ Environment and Sustainability: • Objective: increase the productivity of antibody manufacturing processes to reduce the quantities of plastic and chemical disposables used at Bioventix o 2022: One process converted from plastic flasks to bioreactors in 2022
Slide 14: Significant Shareholders
14 Significant Shareholders Institution Shares % (1000s) Sanford DeLand 1,040 20.0 Total shares = 5,209,333 (Mar Liontrust 583 11.2 2022) Gresham House 465 8.9 Peter Harrison 417 8.0 ▪From permissions, other Hargreaves Lansdown Stockbrokers 343 6.6 available data and TR-1 forms Danske Bank 168 3.2 r
Slide 15: Conclusions and Outlook
15 Conclusions and Outlook ▪ After a slow start to the year, performance has recovered during the remainder of the financial year ▪ Easing of the coronavirus pandemic in key territories has increased activity in routine clinical diagnostic pathways ▪ Troponin revenues have increased significantly ▪